Interestingly, lenvatinib was found to decrease PKC expression and inhibited the PKCa/ZFP64/CSF1 axis, thereby overcoming anti-PD1 resistance in HCC, while sorafenib did not [49]. This evidence concerns the gene PRRT2 and hepatocellular carcinoma.